Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 1.55B +15.4% |
| Revenue (ttm) | 252.25M +223.7% |
| Net Income | -220.77M |
| EPS | -2.51 |
| Shares Out | 89.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,539,015 |
| Open | 18.08 |
| Previous Close | 18.09 |
| Day's Range | 17.29 - 18.11 |
| 52-Week Range | 12.99 - 25.59 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 37.55 (+116.93%) |
| Earnings Date | Nov 2, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $37.55, which is an increase of 116.93% from the latest price.
News
Syndax Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two commercial drugs are driving strong revenue growth, with recurring post-transplant maintenance therapy emerging as a key driver. Multiple pivotal and phase II readouts are expected in the next year, including for IPF and cGVHD, while new pipeline assets targeting NSCLC and myelofibrosis are advancing toward the clinic.
Syndax Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
Strong commercial momentum continues with 85%+ AML market share and robust revenue growth. Multiple pivotal and innovative studies are advancing in AML, IPF, and GVHD, with key data readouts expected by year-end. Early-stage assets in EGFR-mutant lung cancer and myelofibrosis expand the pipeline.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on Septembe...
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying abo...
Syndax price target lowered to $33 from $37 at UBS
UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $33 from $37 and keeps a Buy rating on the shares.
Syndax price target lowered to $40 from $44 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $40 from $44 and keeps an Overweight rating on the shares.
Syndax price target lowered to $38 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Syndax (SNDX) to $38 from $40 and keeps a Buy rating on the shares. The firm says the company delivered another solid…
Syndax Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, with Revuforj and Niktimvo annualizing above $200M each and total revenue up 92% year-over-year. Revuforj's market leadership in menin inhibition and Niktimvo's expanding adoption in chronic GVHD drive confidence in multi-billion-dollar peak sales potential.
Syndax Pharmaceuticals Earnings release: Q2 2026
Syndax Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Syndax Pharmaceuticals Quarterly report: Q2 2026
Syndax Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Syndax Pharmaceuticals Slides: Q2 2026
Syndax Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net...
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo...
Syndax Pharmaceuticals Transcript: R&D Day 2026
The company is advancing a robust pipeline with late-stage and next-gen assets in leukemia, GVHD, IPF, myelofibrosis, and EGFR-mutant NSCLC. Multiple pivotal trials and IND filings are expected through 2027, supported by strong financials and strategic collaborations.
Syndax Pharmaceuticals Slides: FY 2026
Syndax Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on July 14, 2026.
Syndax Pharmaceuticals Press release: FY 2026
Syndax Pharmaceuticals issued a press release on July 14, 2026, disclosing material business information to investors.
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –
Syndax price target lowered to $31 from $34 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Syndax (SNDX) to $31 from $34 and keeps a Buy rating on the shares. The firm updated its acute myeloid…
Syndax presents data from SAVE trial at EHA
Syndax (SNDX) announced that data from the Phase 1/2 SAVE trial of an all-oral regimen of Revuforj, decitabine/cedazuridine, and venetoclax in relapsed or refractory NPM1 mutated, KMT2A-rearranged, or...
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups...
Syndax Pharmaceuticals Transcript: AGM 2026
The meeting covered board introductions, five key proposals, and voting outcomes, with all proposals—including director elections, executive compensation, auditor ratification, and two employee plans—approved by strong majorities. No questions were submitted by stockholders.
Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong R&D and commercialization capabilities have driven rapid product launches and market penetration, especially for Revuforj in AML. Recent clinical data and financial moves support expansion into new indications and geographies, with a robust pipeline and pivotal trials underway.
Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Management highlighted strong commercial momentum for two oncology products, a new $250M convertible debt facility, and robust late-stage and early pipeline progress. Key data readouts for IPF and GVHD are expected in Q4, with ongoing pivotal trials and dominant market share in core indications.